跳转至内容
Merck
CN

S5068

沙美特罗 羟萘甲酸盐

≥98% (HPLC), β2 adrenoceptor agonist, solid

别名:

(±) 4-羟基-a1-[[[6-(4-苯基丁氧基)己基]氨基]间-乙基]-1,3-苯二甲醇 羟萘甲酸盐, GR 33343X 羟萘甲酸盐

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C25H37NO4 · C11H8O3
化学文摘社编号:
分子量:
603.75
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

沙美特罗 羟萘甲酸盐, ≥98% (HPLC), solid

SMILES string

OC(=O)c1ccc2ccccc2c1O.OCc3cc(ccc3O)C(O)CNCCCCCCOCCCCc4ccccc4

InChI key

XTZNCVSCVHTPAI-UHFFFAOYSA-N

InChI

1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)

assay

≥98% (HPLC)

form

solid

color

white

solubility

H2O: slightly soluble, ethanol: slightly soluble, methanol: freely soluble

originator

GlaxoSmithKline

Quality Level

Gene Information

human ... ADRB2(154)

正在寻找类似产品? 访问 产品对比指南

Application

昔萘酸沙美特罗与人血清白蛋白结合用于研究兔的免疫反应。7

Biochem/physiol Actions

β2-肾上腺素能受体激动剂。
昔萘酸沙美特罗是一种 β2 型肾上腺素受体激动剂,具有更持久的支气管扩张作用和抗炎作用。它可以放松气道平滑肌、稳定肥大细胞并调节组胺的释放。昔萘酸沙美特罗对轻度哮喘、慢性阻塞性肺疾病特别有效。5,6

Features and Benefits

该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表,单击此处

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Robert J Slack et al.
The Journal of pharmacology and experimental therapeutics, 344(1), 218-230 (2012-11-08)
Vilanterol trifenatate (vilanterol) is a novel, long-acting β(2)-adrenoceptor (β(2)-AR) agonist with 24 h activity. In this study, we describe the preclinical pharmacological profile of vilanterol using radioligand binding and cAMP studies in recombinant assays as well as human and guinea
Terence L Fodey et al.
Analytica chimica acta, 637(1-2), 328-332 (2009-03-17)
Haptens are low molecular weight compounds that are non-immunogenic and so must be conjugated to carrier molecules to elicit an immune response. Doses of 50-1000 microg protein conjugate have been suggested for immunisation of rabbits with hapten-protein immunogens. Although larger
Basak Isin et al.
PloS one, 7(12), e50186-e50186 (2013-01-10)
Recently available G-protein coupled receptor (GPCR) structures and biophysical studies suggest that the difference between the effects of various agonists and antagonists cannot be explained by single structures alone, but rather that the conformational ensembles of the proteins need to
Adam Barczyk et al.
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 33(196), 187-192 (2013-01-01)
Chronic obstructive pulmonary disease (COPD) is one of the most important diseases because of high and constantly increasing prevalence, morbidity and mortality. An update of the Global strategy for the diagnosis, management, and prevention of COPD - GOLD report was
M Isogaya et al.
Molecular pharmacology, 54(4), 616-622 (1998-10-10)
Transmembrane domains (TMDs) I, II, and VII of the beta2-adrenergic receptor (beta2AR) were replaced, individually or in combination, with the corresponding regions of the beta1AR, and vice versa. The beta2-selective binding of salmeterol was not affected by the exchange of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持